



(51) International Patent Classification:

C07K 16/24 (2006.01) C07K 16/28 (2006.01)
C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2024/060844

(22) International Filing Date:

18 December 2024 (18.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/614,421 22 December 2023 (22.12.2023) US
63/634,353 15 April 2024 (15.04.2024) US
63/664,097 25 June 2024 (25.06.2024) US
63/679,506 05 August 2024 (05.08.2024) US
63/684,260 16 August 2024 (16.08.2024) US
63/713,993 30 October 2024 (30.10.2024) US
63/722,927 20 November 2024 (20.11.2024) US

(71) Applicant: **PROTAGONIST THERAPEUTICS, INC.**
[US/US]; 7707 Gateway Blvd, Suite 140, Newark, California 94560 (US).

(72) Inventors: **BHANDARI, Ashok**; 7707 Gateway Blvd, Suite 140, Newark, California 94560 (US). **ZHANG, Jie**;

306 Carmody Road, St Lucia, Brisbane, Queensland 4072 (AU). **BOURNE, Greg, Thomas**; 306 Carmody Road, St Lucia, Brisbane, Queensland 4072 (AU). **DANIEL, James**; 306 Carmody Road, St Lucia, Brisbane, Queensland 4072 (AU). **DUNCAN, Jack**; 7707 Gateway Blvd, Suite 140, Newark, California 94560 (US). **TANG, Fei**; 306 Carmody Road, St Lucia, Brisbane, Queensland 4072 (AU). **YANG, Bo**; 7707 Gateway Blvd, Suite 140, Newark, California 94560 (US). **TRAN, Tran, Trung**; 306 Carmody Road, St Lucia, Brisbane, Queensland 4072 (AU). **HALLADAY, Jason**; 7707 Gateway Blvd, Suite 140, Newark, California 94560 (US).

(74) Agent: **NG, Rudy, J.**; Bozicevic, Field & Francis LLP, 201 Redwood Shores Pkwy, Suite 200, Redwood City, California 94065 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: HUMAN INTERLEUKIN (IL)-17 CYTOKINE BINDING PEPTIDES

(57) Abstract: The present disclosure provides peptide compounds that inhibit human IL-17 cytokines. The present disclosure also provide pharmaceutical compositions that include the peptide compounds. In addition, the present disclosure also provides methods of use of the peptide compounds, such as methods of treating or preventing diseases, conditions or disorders mediated or associated with IL-17.




FIGURE 2

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*